Search the Newsreel

Tenax Therapeutics (NASDAQ: TENX) ends Q2 2026 with $118M cash

Tenax Therapeutics (NASDAQ: TENX) reported a net loss of $17.8 million for Q2 2026 and $33.5 million for the first half of 2026, primarily due to increased R&D spending on its Phase 3 LEVEL and LEVEL-2 clinical trials for oral levosimendan. The company ended …

Tenax Posts Wider Q2 Loss; Phase 3 Heart Drug Results Due In August

(RTTNews) - Tenex Therapeutics (TENX) on Friday reported second-quarter results, reflecting a wider net loss for the quarter ended June 30, 2026. Company Profile Tenax Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary hypertension and other cardiopulmonary diseases. Its pipeline …

Tenax Therapeutics reports Q2 net loss $17.8M, cash $118.0M; LEVEL Phase 3 topline due Aug 2026

Tenax Therapeutics reported a Q2 2026 net loss of $17.8 million and held $118.0 million in cash. The company increased R&D spending to $12.9 million as it advances two Phase 3 trials for oral levosimendan, with topline data from the LEVEL trial expected in …

Tenax Therapeutics: Q2 Earnings Snapshot

This article provides a brief snapshot of Tenax Therapeutics' Q2 earnings. No specific financial details are available in the provided content. The article is very short and serves as an announcement for the earnings report.

Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tenax Therapeutics reported its second-quarter 2026 financial results, highlighting a cash position of $118.0 million and an extended cash runway through Q2 2028 due to warrant exercises. The company anticipates releasing topline data from its Phase 3 LEVEL clinical trial in August 2026 and …

Stempoint Capital LP Acquires Shares of 188,700 Tenax Therapeutics, Inc. $TENX

BlackRock reports 6.4% stake in Tenax Therapeutics (TENX)

Tenax Therapeutics Price Target Maintained With a $35.00/Share by Cantor Fitzgerald

Cantor Fitzgerald has reiterated its Buy rating on Tenax Therapeutics (NASDAQ: TENX) and maintained a price target of $35.00 per share. This indicates continued confidence from the analyst firm in the company's future performance.

ADAR1 Capital Management LLC Raises Stock Holdings in Tenax Therapeutics, Inc. $TENX

Tenax Therapeutics Inc (TENX) Financial Health: Profitability & Balance Sheet Analysis

Tenax Therapeutics Inc (TENX) has a financial score of 6.95, placing it 178th out of 385 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company's financial health, quality of earnings, operational efficiency, growth potential, and shareholder …

Tenax Therapeutics Inc (TENX) Institutional Confidence

Tenax Therapeutics Inc's (TENX) institutional confidence score is 5.00, placing it 132nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 51.74% quarter-over-quarter to 51.15%. Steven Cohen is the largest institutional shareholder, holding 718.86K shares, despite a 47.34% decrease …

TENX|Tenax Therapeutics Inc|Price:15.785|Chg%:-0.405

This article provides a comprehensive stock analysis of Tenax Therapeutics Inc (TENX), highlighting its strong fundamentals, high growth potential, and "Buy" ratings from analysts with a target price of $35.22. Despite positive financial indicators and outperforming fundamentals, the technical analysis suggests a sideways trading …

Tenax Therapeutics Inc (TENX) Cash Flow

This article provides a detailed historical cash flow statement for Tenax Therapeutics Inc. (TENX), covering operating, investing, and financing activities on a quarterly and annual basis. It includes key metrics such as operating cash flow, net income, capital expenditures, and changes in working capital, …

Tenax Therapeutics Inc (TENX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Tenax Therapeutics Inc (TENX), listing major shareholders and their proportions, as well as categorizing shareholder types. It also provides a historical overview of institutional shareholding, showing an increase in both the number of institutions and shares held …

Tenax Therapeutics Market Sentiment

This article analyzes the market sentiment for Tenax Therapeutics (TENX) by examining analyst consensus, short interest, options flow, and insider activity. The overall sentiment is bullish, with a "Buy" consensus from analysts and a high average price target. However, options flow shows more puts …

Tenax Therapeutics Inc (TENX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Tenax Therapeutics Inc (TENX) stock performance, focusing on its dividend history and stock split events. It indicates that the company has not distributed any dividends in the past five years. The article details several merger-related stock splits, including …

Evercore ISI initiates Tenax Therapeutics stock coverage with outperform rating

Evercore ISI has initiated coverage on Tenax Therapeutics (NASDAQ:TENX) with an outperform rating and a $39.00 price target, citing significant upside potential based on the company's clinical trial in pulmonary hypertension. The firm believes the current stock price implies an undervaluation of the trial's …

Tenax Therapeutics (NASDAQ:TENX) Earns Outperform Rating from Analysts at Evercore

What date does Tenax Therapeutics's (TENX) report Earnings - Earnings Calendar & Announcement

Should I buy Tenax Therapeutics (TENX)

Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know

Total assets of Tenax Therapeutics, Inc. – DUS:YBO0

This page provides financial information for Tenax Therapeutics, Inc. (DUS:YBO0) on the Dusseldorf Stock Exchange, specifically focusing on its total assets. The article indicates that there are no current trade activities visible and presents a placeholder for the company's total asset value, change, and …

Tenax Therapeutics (TENX) gets updated 3.3% ownership filing from Millennium group

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an updated Schedule 13G/A, disclosing a 3.3% beneficial ownership stake in Tenax Therapeutics (TENX). The filing indicates shared voting and dispositive power over 876,230 shares of common stock, explicitly stating that …

ETFs Investing in Tenax Therapeutics, Inc. Stocks

This article lists several ETFs that hold Tenax Therapeutics, Inc. stocks, providing key financial data for each fund such as market value, weight, issuer, expense ratio, and performance. The purpose is to show investors various accessible and lower-risk opportunities for investing in Tenax Therapeutics …

Net income before discontinued operations of Tenax Therapeutics, Inc. – DUS:YBO0

This article provides high-level financial information for Tenax Therapeutics, Inc. (DUS:YBO0), specifically focusing on its net income before discontinued operations. The content is sparse, indicating data for a specific period in the past and originating from TradingView, which aggregates market and financial data.

Average basic shares outstanding of Tenax Therapeutics, Inc. – DUS:YBO0

This article provides financial information for Tenax Therapeutics, Inc. (DUS:YBO0), specifically focusing on its average basic shares outstanding. The content appears to be a stub or an incomplete data entry from a financial platform like TradingView, lacking detailed financial figures but highlighting the company's …

Debt to equity ratio of Tenax Therapeutics, Inc. – DUS:YBO0

The article heading is about the debt to equity ratio of Tenax Therapeutics, Inc. (DUS:YBO0), a company listed on the Dusseldorf Stock Exchange. However, the article provides no actual financial data or details regarding this ratio, only navigation links and copyright information for the …

Analysts Are Bullish on Top Healthcare Stocks: Tenax Therapeutics (TENX), Allogene Therapeutics (ALLO)

Analysts are maintaining a bullish stance on healthcare stocks Tenax Therapeutics (TENX) and Allogene Therapeutics (ALLO). William Blair analyst Matt Phipps reiterated a Buy rating for Tenax Therapeutics with a price target consensus of $37.40, while Sami Corwin, also from William Blair, reiterated a …

Tenax Therapeutics, Inc. Statistics – TRADEGATE:YBO0

This page provides financial statistics for Tenax Therapeutics, Inc. listed under the ticker YBO0 on the Tradegate Exchange. It serves as a hub for key financial metrics and ratios, including valuation, profitability, liquidity, solvency, and per-share statistics, for both annual and quarterly periods. The …

Form 4 Tenax Therapeutics Inc For: 14 July By Investing.com

This article reports on a Form 4 filing for Tenax Therapeutics Inc (TENX) for transactions made on July 14. The company's stock symbol is TENX, and it experienced a -1.41% change. The main content of the article is the announcement of this regulatory filing.